ライフサイエンスコーパス: opioid receptor

1 ssion and function of the full-length 7TM mu-opioid receptor.

2 fficacy-delimited conformations of the kappa opioid receptor.

3 gy of full and partial agonists at the kappa opioid receptor.

4 hich we confirm by locally eliminating the u-Opioid receptor.

5 g of the fundamental signaling mechanisms of opioid receptors.

6 electivity in its actions for KOR over other opioid receptors.

7 uitment) of 22 peptides at each of the three opioid receptors.

8 agonists such as morphine, which acts at mu-opioid receptors.

9 b reveals high selectivity over sigma(2) and opioid receptors.

10 odide demonstrating activation of peripheral opioid receptors.

11 genetic data suggest the importance of delta-opioid receptors.

12 views into the 3-dimensional shapes of all 4 opioid receptors.

13 ons with other receptor systems, notably the opioid receptors.

14 able binding affinity at the u-, delta- or k-opioid receptors.

15 andidate and identified regulation of the mu-opioid receptor 1 gene, Oprm1, as another contributor.

16 Morphine primarily binds to the mu opioid receptor, a prototypical G-protein coupled recept

17 This effect was mediated by presynaptic mu-opioid receptor activation of local parvalbumin (PV(+))-

18 Results indicate that opioid receptor activation plays a significant role in t

19 Opioid receptor activation profoundly depresses PAG and

20 t antidepressant effects of ketamine require opioid receptor activation.

21 Since then, >20 peptides with opioid receptor activity have been discovered, all of wh

22 ed on our previous report of increased delta opioid receptor activity in Gpr88 null mice, we investig

23 Since opioid receptor activity plays a central role in the dev

24 these precursors generates >20 peptides with opioid receptor activity, leading to a long-standing que

25 cological mechanisms, including tramadol (mu-opioid receptor agonism) and tizanidine (alpha2 agonism)

26 mechanism of action is attributed to mild mu-opioid receptor agonism, serotonin and norepinephrine me

27 Salvinorin A (SA) is a kappa-opioid receptor agonist and atypical dissociative halluc

28 self-administration of the high-efficacy mu opioid receptor agonist fentanyl and characterized MCAM

29 her buprenorphine or the G protein-biased mu opioid receptor agonist TRV130.

30 The opioid receptor agonist, leu-enkephalin, was predicted t

31 aversion induced by thermal pain or a kappa opioid receptor agonist.

32 ity on the A-ring in its activity as a kappa-opioid receptor agonist.

33 reducing inhibition of cAMP signaling by mu-opioid receptor agonists DAMGO and morphine.

34 nce for the psychotomimetic effects of kappa opioid receptor agonists in healthy volunteers and their

35 IH.SIGNIFICANCE STATEMENT Clinically used mu-opioid receptor agonists such as fentanyl can produce hy

36 ervised withdrawal include treatment with mu-opioid receptor agonists, (eg, methadone), partial agoni

37 We propose that G protein-biased mu opioid receptor agonists, currently in development as an

38 phosphorylation on the C terminus of the mu-opioid receptor alters acute desensitization and interna

39 viously shown that desensitization of the mu-opioid receptor and interaction with beta-arrestins is c

40 e distribution of Mg(2+) and Na(+) in the mu-opioid receptor and their impact on its function.

41 proaches include inhibition of peripheral mu opioid receptors and blockade of downstream signalling m

42 and raphe nucleus), all of which express mu opioid receptors and directly respond to opioids.

43 erties emerging from the cellular biology of opioid receptors and discuss potential relevance to ther

44 stem cells (NSCs) in which the expression of opioid receptors and endogenous opioid agonists is low.

45 oncomitant opioid release could downregulate opioid receptors and promote the development of obesity.

46 Moreover, genetic models of G protein-biased opioid receptors and replication of previous knockout ex

47 ility to modulate cell responses through the opioid receptors and TCRs.

48 We describe the interactions between kappa opioid receptors and the dopaminergic pathways that are

49 amic (i.e., pseudoirreversible binding to mu opioid receptors) and not pharmacokinetic factors play a

50 sted peptides are able to activate the three opioid receptors, and many of them exhibit agonist-direc

51 hormones (estrogen and progesterone), delta-opioid receptors, and T cells of the adaptive immune sys

52 washout of DAMGO or by application of the mu-opioid receptor antagonist CTAP, suggesting an inhibitor

53 MCAM (0.1-0.32 mg/kg) or the opioid receptor antagonist naltrexone (0.001-0.032 mg/kg

54 New forms of the opioid receptor antagonist naltrexone are also being stu

55 VT administration of OrxA+/-DynA+/-the kappa-opioid receptor antagonist nor-binaltorphimine (NorBNI)

56 A combination of olanzapine and the opioid receptor antagonist samidorphan is under developm

57 Naltrexone is a nonselective opioid receptor antagonist used as a treatment for alcoh

58 Methocinnamox (MCAM), a mu opioid receptor antagonist with a long duration of actio

59 ion of norbinaltorphimine, a selective kappa opioid receptor antagonist, in the BLA reduced alcohol c

60 ced by intrapericardial naloxone, a specific opioid receptor antagonist.

61 lpiperazines 4 and 5 were reported to be pan opioid receptor antagonists, while 6 was a MOR agonist.

62 rials suggest that some medications, such as opioid-receptor antagonists, may be helpful.

63 However, it is unknown if opioid receptors are also involved in ketamine's antisui

64 ic utility in various addictions where brain opioid receptors are implicated, such as gambling disord

65 der the microscope." SIGNIFICANCE STATEMENT: Opioid receptors are major pharmacological targets, but

66 primary events in the broader picture of mu opioid receptor-associated brain aversion networks.

67 However, it is unknown if mu-opioid receptor availability is altered in-vivo or relat

68 G, BED patients show widespread losses of mu-opioid receptor availability together with presynaptic d

69 , naltrexamine-acylimidazole (NAI), to label opioid receptors based on a chemical approach termed 'tr

70 eciofoline levels in kratom, we compared the opioid receptor binding activity of speciofoline, mitrag

71 ion in a dose-dependent manner determined by opioid receptor binding and [(35)S] guanosine 5'-3-O-(th

72 esics whose mechanisms do not involve the mu opioid receptor but that have high analgesic potency and

73 Activation of the opioid receptors by opiates and synthetic drugs leads to

74 is an increased demand for understanding how opioid receptors can be allosterically modulated to guid

75 peroxiredoxin 6 (PRDX6) is recruited to the opioid receptor complex by c-Jun N-terminal kinase (JNK)

76 Opioid receptors couple to various heterotrimeric Galpha

77 ich depends on subregional differences in mu-opioid receptor coupling to the downstream cAMP/PKA intr

78 ogenous opioids is due to the efficacy of mu-opioid receptor coupling to the downstream cAMP/PKA intr

79 Although ultra-high-resolution opioid receptor crystal structures have revealed a speci

80 the mu opioid receptor (muOR) and the delta opioid receptor (deltaOR) heteromer as a credible novel

81 t controls the surface delivery of the delta opioid receptor (deltaR).

82 phorylation as key step that drives acute mu-opioid receptor desensitization and long-term tolerance.

83 Opioid receptors diffuse rapidly throughout the axon sur

84 rder to resolve the interactome of the delta-opioid receptor (DOPr) in its native in vivo environment

85 ioids from the inflamed colon activate delta-opioid receptors (DOPr) in endosomes of nociceptors.

86 In contrast, delta-opioid receptor (DOR) agonists disinhibited ACC pyramida

87 Delta opioid receptor (DOR) agonists have been identified as a

88 long-acting, bifunctional MOR agonist/delta-opioid receptor (DOR) antagonist analgesic devoid of tol

89 es of mu-opioid receptor (MOR) agonist/delta-opioid receptor (DOR) antagonist bicyclic core peptidomi

90 es of mu-opioid receptor (MOR) agonist/delta-opioid receptor (DOR) antagonist ligands to serve as pot

91 Activation of the delta-opioid receptor (DOR) produces similar analgesia with re

92 The delta opioid receptor (DOR), a physiologically relevant protot

93 pioid receptor (MOR) agonist and delta/kappa opioid receptor (DOR/KOR) antagonist with potent antinoc

94 Enkephalins, endogenous ligands for delta opioid receptors (DORs), are highly enriched in the nucl

95 exposure, involvement of the dynorphin/kappa opioid receptor (DYN/KOR) system in binge-like drinking

96 Animal studies indicate that the kappa-opioid receptor/dynorphin system plays an important role

97 ces in understanding the cellular biology of opioid receptors, emphasizing particular topics discusse

98 Importantly, opioid receptors expressed in the peripheral nervous sys

99 re work will identify the nature of these mu opioid receptor-expressing neurons throughout reward-ave

100 lthough differences in stress reactivity and opioid receptor expression occurred, overall they were r

101 stress reactivity together with spinal/brain opioid receptor expression were also measured.

102 ioid peptide (NOP) receptor, a member of the opioid receptor family, are under active investigation a

103 acterized than those of other members of the opioid receptor family.

104 these studies conducted systemic analyses of opioid receptor function, often generalizing findings fr

105 In conclusion, all members of the opioid receptor gene family express circRNAs, with Oprm1

106 Extensive 3' alternative splicing of the mu opioid receptor gene OPRM1 creates multiple C-terminal s

107 The mu-opioid receptor gene undergoes extensive alternative spl

108 x transmembrane (TM) domains of the mouse mu-opioid receptor gene, in enhancing expression of the ful

109 Allelic differences in the human mu opioid receptor gene, notably the A118G single nucleotid

110 The mu-opioid receptor gene, OPRM1, undergoes extensive alterna

111 linear mRNAs (linRNA), mouse, rat, and human opioid receptor genes generate exonic circRNA isoforms.

112 In addition, we observed that other opioid receptor genes including delta, kappa, and nocice

113 own substantially in recent years and the mu-opioid receptor has been one of the most intensively stu

114 rs of G protein-coupled receptors, including opioid receptors, have been proposed as possible therape

115 w different opioids affect signaling through opioid receptors; how opioid receptors modulate circuitr

116 First, Dbx1 preBotC neurons express kappa-opioid receptors in addition to mu-opioid receptors that

117 The activation of opioid receptors in peripheral inflamed tissue can reduc

118 g the distribution and physiological role of opioid receptors in the CNS of wild type animals.

119 rate thought to be caused by stimulation of opioid receptors in the inspiratory-generating regions o

120 naloxone, suggesting the participation of mu-opioid receptors in the reinforcing properties of sufent

121 t of GPR88 co-expression on the signaling of opioid receptors in vitro and revealed that GPR88 inhibi

122 began with Portoghese's work directed toward opioid receptors, in the early 1980s.

123 te analgesic tolerance to morphine and kappa opioid receptor inactivation in vivo.

124 When the expression of opioid receptors increased and the expression of Tet1 de

125 or sufentanil when given the preferential mu-opioid receptor inverse agonist naloxone, suggesting the

126 rom clinical studies for dynorphin and kappa opioid receptor involvement in the pathology of both the

127 systemic side effects, targeting peripheral opioid receptors is an attractive alternative treatment

128 Identifying neurons that have functional opioid receptors is fundamental for the understanding of

129 wed good affinity and selectivity for the mu-opioid receptor (K(I) of 59.2 nM, EC(50) of 12.9 nM, E(M

130 or insula with a downregulation of the kappa opioid receptor (Kappa), as well as decreased DNA methyl

131 The kappa opioid receptor (kappaOR) is an important target for pai

132 tressful experiences potently activate kappa opioid receptors (kappaORs).

133 acilitate neurogenesis were also observed in opioid receptor-knockout NSCs.

134 promoted phosphorylation of the mouse kappa opioid receptor (KOPR) at residues S356, T357, T363, and

135 Studies have shown kappa-opioid receptor (KOR) abnormalities in addictive disorde

136 pherally active, potent, and selective kappa-opioid receptor (KOR) agonists comprising the ethylenedi

137 Kappa opioid receptor (KOR) agonists produce analgesic and ant

138 Kappa opioid receptor (KOR) agonists show promise in ameliorat

139 rk has established a role for both the Kappa Opioid Receptor (KOR) and its endogenous ligand dynorphi

140 il approach evaluated the potential of kappa-opioid receptor (KOR) antagonism for treating anhedonia

141 Administration of the kappa-opioid receptor (KOR) antagonist JDTic (30 mg/kg, i.p.)

142 Administration of a kappa-opioid receptor (KOR) antagonist reduced stress effects

143 anhedonia, 8 weeks of treatment with a kappa-opioid receptor (KOR) antagonist resulted in significant

144 Kappa opioid receptor (KOR) antagonists are being developed as

145 kappa opioid receptor (KOR) antagonists are potential pharmaco

146 al member of the receptor-inactivating kappa opioid receptor (KOR) antagonists, norbinaltorphimine (n

147 Our goal was to investigate changes in kappa-opioid receptor (KOR) availability in the human brain us

148 We evaluated the occupancy of the kappa opioid receptor (KOR) by naltrexone measured with [(11)C

149 regions of the NAc, activation of the kappa opioid receptor (KOR) decreases the reinforcing properti

150 The kappa-opioid receptor (KOR) has emerged as a promising target

151 investigated the potential role of the kappa opioid receptor (KOR) in the therapeutic effect of naltr

152 The kappa-opioid receptor (KOR) is implicated in various neuropsyc

153 Despite a growing interest in the kappa opioid receptor (KOR), KOR-selective fluorescent probes

154 se (JNK) by the G(i/o) protein-coupled kappa opioid receptor (KOR), mu opioid, and D2 dopamine recept

155 d that this effect is dependent on the kappa opioid receptor (KOR), specifically in the lateral hypot

156 that this response is regulated by the kappa opioid receptor (KOR).

157 : dopamine, mu-opioid receptors (MOR), kappa opioid receptors (KOR), and brain-derived neurotrophic f

158 tion of expression and the function of kappa opioid receptors (KORs) and its endogenous ligand dynorp

159 Kappa opioid receptors (KORs) have been characterized as an av

160 e dynorphin, which acts at presynaptic kappa-opioid receptors (KORs) on dopaminergic afferents and ca

161 led unexpectedly to potent and selective mu-opioid receptor ligands.

162 e current status of established and novel mu-opioid-receptor ligands that are proposed to be biased l

163 Inactivation of opioid receptors limits the therapeutic efficacy of morp

164 stic begs one to question whether peripheral opioid receptors maintain anatomically unique roles, and

165 a high priority in medical sciences, but mu-opioid receptors mediate both the analgesic and addictiv

166 ence for the important role of nociceptor mu-opioid receptor-mediated calcium signaling and periphera

167 s research has demonstrated a role for kappa opioid receptor-mediated signaling in escalated alcohol

168 In this Review, we focus on the opioid receptors, members of GPCR family A, and highligh

169 ositive allosteric modulator (PAM) of the mu-opioid receptor (micro-OR).

170 Functional selectivity at the micro opioid receptor (microR), a prototypical G-protein-coupl

171 The idea that biased agonists at the mu-opioid receptor might provide a therapeutic advantage in

172 Of the five 6TM variants in mouse, mouse mu-opioid receptor (mMOR)-1G is abundant and conserved from

173 udy establishes a novel function of mouse mu-opioid receptor (mMOR)-1G, a truncated splice variant wi

174 hancing expression of the full-length 7TM mu-opioid receptor, mMOR-1.

175 fect signaling through opioid receptors; how opioid receptors modulate circuitry involved in processe

176 e tyrosine kinase, c-Src, participates in mu opioid receptor (MOP) mediated inhibition in sensory neu

177 sign of bilorphin, a potent and selective mu-opioid receptor (MOPr) agonist (K (i) 1.1 nM).

178 G protein-biased agonists of the mu-opioid receptor (MOPr) have been proposed as an improved

179 The mu-opioid receptor (MOPr) is a clinically important G prote

180 e 14-position of the morphinan as a mixed mu opioid receptor (MOR) agonist and delta/kappa opioid rec

181 Here we report that the selective mu opioid receptor (MOR) agonist fentanyl dose-dependently

182 We have previously reported a series of mu-opioid receptor (MOR) agonist/delta-opioid receptor (DOR

183 verted a metabolically unstable series of mu-opioid receptor (MOR) agonist/delta-opioid receptor (DOR

184 mu opioid receptor (MOR) agonists have been widely applied

185 Short-acting mu-opioid receptor (MOR) agonists have long been used for t

186 Mu-opioid receptor (MOR) agonists potently inhibited MThal

187 Clinical u-opioid receptor (MOR) agonists produce hyperalgesic prim

188 there was no difference in the ability of mu-opioid receptor (MOR) agonists to inhibit sIPSCs in POMC

189 effects of the systemic administration of mu-opioid receptor (MOR) agonists.

190 ral modification of previously identified mu opioid receptor (MOR) antagonist NAN, a 6alpha-N-7'-indo

191 Nasal spray formulations of naloxone, a mu-opioid receptor (MOR) antagonist, are currently used for

192 the sigma(1) receptor (sigma(1)R) and the mu-opioid receptor (MOR) are reported.

193 the sigma-1 receptor (sigma(1)R) and the mu-opioid receptor (MOR) are reported.

194 veloping alcohol dependence (AD) and high mu-opioid receptor (MOR) availability in early abstinence i

195 cent advancements in our understanding of mu-opioid receptor (MOR) function and regulation and the ro

196 report convergent evidence for decreased mu-opioid receptor (MOR) function in the female rat LC.

197 In this study, we found that the mu opioid receptor (MOR) gene, Oprm1, is highly expressed i

198 rs1799971) gene variant encoding the N40D u-opioid receptor (MOR) has been associated with dependenc

199 the regulation and internalization of the mu-opioid receptor (MOR) have been linked to the severity o

200 The mu opioid receptor (MOR) is a diversely regulated target fo

201 Further, we demonstrate that the mu-opioid receptor (MOR) is expressed on DG NSCs and that M

202 The mu-opioid receptor (MOR) is the cellular mediator of the ef

203 in 2 [EM2; the highly specific endogenous mu-opioid receptor (MOR) ligand] induces antinociception th

204 is study describes signaling diversity of mu opioid receptor (MOR) ligands in terms of logistic and o

205 SIGNIFICANCE STATEMENT: The mu-opioid receptor (MOR) localized in the ventral tegmental

206 Agonist binding to the mu opioid receptor (MOR) results in conformational changes

207 ylation of sites on the C terminus of the mu-opioid receptor (MOR) results in the induction of acute

208 Modulating mu-opioid receptor (MOR) signaling is one way to potentiall

209 ce was thought to occur by termination of mu-opioid receptor (MOR) signaling via desensitization and

210 The brain mu-opioid receptor (MOR) system modulates a multitude of se

211 The central mu-opioid receptor (MOR) system modulates numerous seasonal

212 Opioids target the mu-opioid receptor (MOR) to produce unrivaled pain manageme

213 igand bias downstream of activation of the u-opioid receptor (MOR) toward G protein signaling and awa

214 nique opioid analgesic that activates the mu-opioid receptor (MOR) without efficiently promoting its

215 imary brain target of opioid drugs is the mu-opioid receptor (MOR), encoded by the OPRM1 gene, which

216 At the mu-opioid receptor (MOR), G protein-biased ligands have bee

217 Based on studies using mutations of the u-opioid receptor (MOR), phosphorylation of multiple sites

218 ivate a potassium conductance through the mu-opioid receptor (MOR), suggesting for the first time tha

219 Here, we use the mu opioid receptor (MOR), the primary target for opioid ana

220 Splice variants of the mu opioid receptor (MOR), which mediates opioid actions, ha

221 red from opioid-primed rats, it induced a mu-opioid receptor (MOR)-dependent increase in [Ca(2+)](i)

222 h their respective GPCRs, GalR1-3 and the mu-opioid receptor (MOR).

223 that tianeptine is a full agonist at the mu opioid receptor (MOR).

224 in circuits by opposing the actions of the u-opioid receptor (MOR).

225 gered by classic opioids-in particular the u-opioid receptor (MOR).

226 scaffold to block internalization of the mu-opioid receptor (MOR).

227 The mu-opioid receptor (MOR, OPRM1) has important roles in dive

228 t position 6 that emerged as potent mu/delta opioid receptor (MOR/DOR) agonists with peripheral antin

229 Mu-opioid receptors (MOR) in the striatum play a key role i

230 f acute physical exercise on the cerebral mu-opioid receptors (MOR) of 22 healthy recreationally acti

231 to be key players in addiction: dopamine, mu-opioid receptors (MOR), kappa opioid receptors (KOR), an

232 The mu-opioid receptors (MOR, OPRM1) mediate the effects of bet

233 We used PET and the mu-opioid-receptor (MOR)-specific ligand [(11)C]carfentanil

234 Here we show that mu-type opioid receptor (MOR1) levels were severely decreased in

235 ect was associated with the activation of mu-opioid receptors (MORs) and an increase in beta-endorphi

236 Mu opioid receptors (MORs) are central to pain control, dru

237 In this study, we found that more mu opioid receptors (MORs) are expressed in GABA neurons in

238 mu-Opioid receptors (MORs) are expressed peripherally and c

239 Mu-opioid receptors (MORs) are the primary site of action o

240 u-Opioid receptors (MORs) are widely distributed throughou

241 Our previous work identified mu opioid receptors (MORs) as mediators of synapse-specific

242 We found that mu opioid receptors (MORs) expressed by primary afferent no

243 Activation of somatic mu-opioid receptors (MORs) in hypothalamic proopiomelanocor

244 genetic manipulations to alter or remove mu-opioid receptors (MORs) with anatomic and cell type spec

245 by desensitization and internalization of mu-opioid receptors (MORs).

246 ratory depression due to the activation of u-opioid receptors (MORs).

247 be mediated by simultaneous activation of mu-opioid receptors (MORs, encoded by the Oprm1 gene) at mu

248 258747 blocked the internalization of the mu-opioid receptor most efficaciously because it has the ab

249 rstanding the activation mechanism of the mu-opioid receptor (mu-OR) and its selective coupling to th

250 is generally thought that the three types of opioid receptors (mu, delta, kappa) are activated by end

251 mu-Opioid receptors (mu-ORs) play a critical role in the mo

252 medullary slices from neonatal mice, the mu-opioid receptor (muOR) agonist DAMGO slowed burstlet gen

253 de-based opioid derivatives targeting the mu opioid receptor (muOR) and the delta opioid receptor (de

254 t beta-arrestin biased agonist, binds the mu-opioid receptor (muOR).

255 perdinylindoles were developed as nociceptin opioid receptor (NOP) partial agonists to explore a phar

256 aminergic neurons in the VTA by acting on mu-opioid receptors on RMTg neurons and their terminals ins

257 Furthermore, pharmacological blockade of mu opioid receptor or Toll-like receptors complex failed to

258 opment emphasizing sensitivity to changes in opioid receptor (OR) occupancy over high affinity.

259 Opioid receptors (ORs) are among the best-studied G prot

260 While it is known that opioid receptors (ORs) are densely expressed in both the

261 injury, and their cognate G protein-coupled opioid receptors (ORs) are expressed on immune cells.

262 Opioid receptors (ORs) are undisputed targets for the tr

263 ulation of agonist and antagonist binding to opioid receptors (ORs) by sodium (Na+) has been known fo

264 Opioid receptors (ORs) convert extracellular messages to

265 al raphe nucleus (DRN), with differential mu-opioid receptor regulation, each targeting different pos

266 The activation of central mu-opioid receptors related to CXCL1-CXCR2 signaling plays

267 constraining aromatic residues in the kappa opioid receptor selective antagonist arodyn (Ac[Phe(1,2,

268 se findings establish an important aspect of opioid receptor signaling and suggest that ROS induction

269 istologic evidence suggesting abnormal kappa opioid receptor signaling in schizophrenia.

270 Here, we show that kappa opioid receptor signaling in the bed nucleus of the stri

271 Our data shows that NPR-17 opioid receptor signaling suppressed pheromone biosynthe

272 eficial and maladaptive roles of opioids and opioid receptor signaling.

273 e and hyperalgesia are complex, involving mu opioid receptor signalling pathways that offer opportuni

274 Further diversity in opioid receptor structure is driven by both genetic vari

275 irability of G protein-biased agonists at mu-opioid receptor substantiated by what we know of the phy

276 ition of KOR, but not of the delta or the mu opioid receptor subtypes, fully blocked CR-induced hypot

277 nagement; however, the often-forgotten delta opioid receptor system has been identified as a novel th

278 t is well known that activation of the kappa opioid receptor system modulates negative affect and dys

279 innovative experimental data indicates that opioid receptor systems are differentially modulated dep

280 na speciosa (kratom), had higher affinity at opioid receptors than at adrenergic receptors while the

281 hadone-specific active conformation of the u-opioid receptor that has thus far eluded experimental st

282 ly restricted and selective agonist of kappa opioid receptors that are considered to be important in

283 ess kappa-opioid receptors in addition to mu-opioid receptors that heretofore have been associated wi

284 gulates the endosomal localization of the mu opioid receptor, the primary target of opioid analgesics

285 atosensory neurons is tightly regulated by u-opioid receptors through the signaling of Gbetagamma pro

286 pioid agonists that preferentially act at mu-opioid receptors to activate G protein signaling over be

287 oid reduction of pain depends on coupling of opioid receptors to Galphai/o family members.

288 r in vivo (in animals), using antagonists of opioid receptors to infer endogenous peptide activity, a

289 nd drug cravings, despite acting on the same opioid receptors triggered by classic opioids-in particu

290 of these peptides binds to all three of the opioid receptor types (mu, delta, or kappa), albeit with

291 C]carfentanil, a selective radioligand for u-opioid receptors (uORs).

292 g mouse TRPC4beta and the G(i/o) -coupled mu opioid receptor, we investigated the role of intracellul

293 Focusing on opioid receptors, we directly demonstrate differences be

294 d a view into the molecular movements of the opioid receptors, which itself gives rise to the complex

295 is is consistent with nalmefene's actions on opioid receptors, which modulate the mesolimbic dopamine

296 atory factor 1, CXCR3, alpha (1)-AR, and the opioid receptors, which results in differential signalin

297 function as partial agonists of the human u-opioid receptor, while speciofoline does not exhibit mea

298 etermined entirely by heteromerization of mu-opioid receptors with galanin Gal1 receptors, rendering

299 opioidergic mechanisms, as antagonism of mu-opioid receptors with systemically-administered naltrexo

300 is that a G protein-biased agonist at the mu-opioid receptor would be an effective analgesic without